The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksel...
May 02 2019 - 7:00AM
PRESS RELEASE
Lund 2 May,
2019 - Active Biotech (NASDAQ, STOCKHOLM:ACTI) announce that
the Election Committee of Active Biotech AB (publ) proposes that
Michael Shalmi and Uli Hacksell are appointed new members of the
Board of Directors and that Michael Shalmi is appointed Chairman of
the Board of Directors. Mats Arnhög and Magnhild Sandberg have
declined re-election.
The Election
Committee's proposal to the Annual General Meeting
The Election Committee, which is composed of Mats Arnhög (Chairman
of the Board), Johnny Sommarlund (MGA Holding), Tomas Billing
(Nordstjernan) and Reza Khiabani (own holdings), proposes the
following:
Chairman of the
Meeting: attorney-at-law Erik Sjöman.
Number of members and deputy
members of the Board of Directors: four ordinary members with no
deputies.
Fees payable to
the Board of Directors: SEK 500.000 to the Chairman of the
Board and SEK 200.000 to each of the other Board members who are
not employed by the company. Michael Shalmi may also receive
remuneration on market terms for work performed for the company
outside the scope of the Board work (for additional information,
see below).
Board of
Directors: re-election of Peter Sjöstrand and Peter Thelin and
appointment of Michael Shalmi and Uli Hacksell as new members of
the Board.
Chairman of the
Board: Michael Shalmi.
Number of
auditors and deputy auditors: one auditor with no deputies.
Fees payable to
the auditor: in accordance with approved invoices within the
scope of the tender.
Auditor:
re-election of KPMG AB.
The proposal regarding auditor is
in accordance with the recommendation by the Board of
Directors.
Furthermore, the Election
committee proposes that the Election Committee for the Annual
General Meeting 2020 shall be appointed in accordance with
principles corresponding to those previously applied.
Information on
the Board members proposed to be appointed
Michael Shalmi, born in 1965 and Danish citizen graduated as a
physician from University of Copenhagen and obtained his MBA
following studies at Scandinavian International Management
Institute in Copenhagen. Previously, Michael Shalmi served as
Managing Director and Head of Principal Investments of Novo
Holdings A/S. He holds a position as director of the Supervisory
Board of Evotec AG, and the Board of Momentum Gruppen A/S.
Uli Hacksell, born in 1950, is a
pharmacist, Doctor of Pharmaceutical Science and associate
Professor at Uppsala University. He is acting CEO and member of the
Board of Medivir AB. In addition, Uli Hacksell holds a position as
Chairman of the Board of Adhera Therapeutics Inc. and as member of
the Board of Beactica AB, Cerecor Inc, InDex Pharmaceuticals AB and
Uppsala University.
For further information on the
proposed members of the Board of Directors, please see the Election
Committee's complete proposal which is available at Active
Biotech's website, www.activebiotech.com.
Other
information
The Election Committee has been informed that Active Biotech
intends to enter into a consulting agreement with Michael Shalmi,
pursuant to which Michael Shalmi and the management of the company
jointly shall develop a new business plan for the company based on
a full evaluation of the clinical and commercial opportunities of
Active Biotech's assets. This task, which is an assignment outside
the scope of Michael Shalmi's task as Chairman of the Board, shall
be carried out during the period up to and including December 31,
2019, for which it is intended that Michael Shalmi shall receive a
remuneration of SEK 1.1 million for the assignment.
In addition, the Election
Committee has been informed that the main owners of Active Biotech,
MGA Holding and Nordstjernan, have issued call options on market
terms for 1.500.000 shares in Active Biotech to Michael Shalmi.
For further
information, please contact:
Helén Tuvesson, CEO
Tel. +46 46 19 21 56
Hans Kolam, CFO
Tel. +46 46 19 20 44
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties in development for neurodegenerative
diseases. ANYARA (naptumumab), an immunotherapy, in development for
cancer indications in partnership with NeoTX Therapeutics Ltd.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(org.nr 556223-9227)
Box 724, 220 07 Lund
Tel. +46 46 19 20 00
This information is information
that Active Biotech AB is obliged to make public pursuant to the EU
Market Abuse Regulation. This information was submitted for
publication, through the agency of the contact person set out
above, at 13.00 p.m. CET on May 2, 2019.
The Election Committee of Active
Biotech AB
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Sep 2023 to Sep 2024